Cereno Scientific AB logo

CRNO TO1 B - Cereno Scientific AB News Story

SEK0.495 0.0  5.1%

Last Trade - 15/01/21

Sector
Healthcare
Size
Micro Cap
Market Cap £7.15m
Enterprise Value £6.49m
Revenue £n/a
Position in Universe 1678th / 1866

BRIEF-Cereno Scientific's Phase II Clinical Trial Postponed Due To COVID-19

Mon 30th March, 2020 8:25am
March 30 (Reuters) - Cereno Scientific AB  CRNOSb.TE :
    * CERENO SCIENTIFIC'S PHASE II CLINICAL TRIAL POSTPONED DUE
TO
COVID-19
    * DUE TO GLOBAL SPREAD OF SARS-COV-2 VIRUS CERENO SCIENTIFIC
ANNOUNCES THAT COMPANY WILL POSTPONE PLANNED PHASE II CLINICAL
TRIAL WITH COMPANY'S LEAD COMPOUND CS1. START OF STUDY WAS
PREVIOUSLY PLANNED FOR MID-YEAR 2020.
    * IS ADJUSTING PLANNED ACTIVITIES TO START BY END OF YEAR,
BUT IS
PREPARED FOR FURTHER ADJUSTMENTS IF NEEDED, DUE TO UNCERTAINTY
OF FURTHER DEVELOPMENT OF PANDEMIC
    * THERE ARE NO POSSIBILITIES TO START PHASE II STUDY IN
ELECTIVE
ORTHOPEDIC SURGERY, AS PLANNED KNEE JOINT SURGERY IS DOWN
PRIORITIZED IN HOSPITALS FOR BENEFIT OF EFFECTIVE CARE TO
COVID-19 INFECTED PATIENTS

Source text for Eikon:  ID:nWkr7kZCzC 
Further company coverage:  CRNOSb.TE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.